In 2020, scientists Emmanuelle Charpentier and Jennifer Doudna won the Nobel Prize in Chemistry for their work on CRISPR-Cas9. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) as a technology is akin to a pair of gene scissors that can target and cut a DNA sequence. This revolutionary gene editing method allows scientists to rewrite the genetic code in almost any organism, while being cheaper, simpler and more precise than any of its gene-editing predecessors. Unsurprisingly, interest in this field is increasing at an exponential rate. New innovations in agriculture, treatments of debilitating illnesses, and genetic prevention of inherited illness are all being explored in detail.
While CRISPR as a technology is both novel and exciting, assessing which companies, inventors and new entrants to keep your eye on can be a challenging task. Typically, concepts such as influence can be difficult to pin down and are at the mercy of subjectivity. In this webinar, the featured speaker explores ways to quantify such ideas and to pin down exactly who the “influential” entities are by the relationships they foster. The vehicle used to explore this idea is patent co-ownership. Patents are often a key component in the protection and commercialisation strategies of businesses, and co-ownership of patents can point to relationships between organisations.
As CRISPR is a relatively new technology, innovations tend to require lots of research and are often capital intensive, as is typically the case with developments in the life science industry, so these collaborative relationships become more common. Network analysis allows the leveraging of graph theory to make sense of a high volume of connections. These connections can be quantified and assessed to compare their relative quality, and therefore the level of influence an entity might have within the context of the industry network.
Join this webinar to learn more about leveraging patent intelligence and network analysis to quantify technology influence in CRISPR.
Frazer Kearl, Research & Data Analyst, PatSnap
Frazer is an experienced analyst with a background in computational chemistry. In his own words: “electrons are pretty small and I wanted to think bigger!”. He spends his days coming up with creative ways to leverage PatSnap’s data into insightful innovation analysis.Message Presenter
Who Should Attend?
- Director and above
- Persona: IP and R&D
- LinkedIn Industries: Biotechnology, Hospital and Healthcare, Medical Devices, Medical Practice, Pharmaceuticals, Research, Veterinary
What You Will Learn
Attendees will learn about:
- Beginning to think about technological influence
- Leveraging patents as an indicator of relationships between businesses
- An introduction to Network Analysis
- Quantifying the influence of organisations involved in CRISPR
PatSnap is a patent search and analytics platform that combines intuitive functionality, world leading patent and life sciences datasets and cutting-edge AI together in one platform. Drawing upon both our own patent sequence extracts and world-renowned manual curation, we offer the world’s most comprehensive patent biological sequence platform. The deep integration of this data with our global patent database, our NPL collection and chemical platform makes complex search strategies simple, and enables seamless collaboration with other IP stakeholders within the business.